Skip to content

Assessing the Presence of Casomorphins in Human Plasma After Dairy Ingestion

Assessing the Presence of Casomorphins in Human Plasma After Dairy Ingestion

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00360919
Enrollment
28
Registered
2006-08-07
Start date
2006-09-30
Completion date
2010-12-31
Last updated
2012-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Food Habits

Keywords

casomorphin, cheese, craving, casein, milk

Brief summary

This purpose of this study is to perform a pilot investigation to determine if opioid peptides such as casomorphin can be detected in human plasma after cheese ingestion.

Detailed description

Cheese is one of the most commonly craved foods, suggesting the possibility of opiate activity, as has been demonstrated with other craved foods, particularly chocolate. Like other dairy products, cheese contains casein, which is the major protein in cow's milk. This is unlike human milk, in which the primary protein is whey. Casein includes αs1-, αs2-, β- , and κ-casein, with αs1 and β forms predominating. Human and bovine casein molecules are cleaved during digestion to release opioid peptides that are believed to have biological properties relevant to infant physiology and behavior. Specifically, β-casein is cleaved to form β-casomorphins. Like other opiate agonists, β-casomorphins prolong gastrointestinal transit time and have an antidiarrheal effect. Casomorphin receptor binding has been demonstrated in opiate receptor assays and bioassays. Duodenal aspirates from human volunteers given cow's milk have demonstrated the presence of several casomorphins, particularly β-casomorphin-7. Few studies have assessed the presence or action of casomorphins in humans. The ability of casein-derived opioid peptides to pass into the bloodstream is not well characterized, and is the subject of the present study.

Interventions

BEHAVIORALcheese ingestion

On study day 1, approximately half of the participants will consume a breakfast of fruits and vegetables, whereas the other half of participants will consume a meal consisting of 9 oz. of cheese. Blood samples will be collected from participants immediately prior to consumption of the meals, and then again at regular intervals for up to 8 hours following the meals. At least 3 days later, participants will return for study Day 2. The participants will receive the second meal. Blood samples will then be collected immediately prior to consumption of the test meal and for up to 8 hours after the meal.

Sponsors

Physicians Committee for Responsible Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age greater than 18 years * Male or female * Either self-described as having a strong liking for cheese, or have been following a vegan diet for a least the previous six months.

Exclusion criteria

* Unstable medical status * Physical condition affecting eating behavior, digestion, or intestinal absorption * Dairy allergy or lactose intolerance * Pregnancy * History of severe mental illness * Smoking during the past six months * Alcohol consumption of more than two drinks per day * History of substance abuse or dependency followed by any current use * Inordinate fear of blood draws

Design outcomes

Primary

MeasureTime frame
casomorphin quantificationMeasurements will be collected on designated studys within 12-hour time frame

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026